I think you're dead on. .20 by the end of the year is realistic. I personally don't expect the PPS to significantly increase beyond that until we show some kind of revenue. When we can actually report income on our books is when the PPS will start making significant moves.

Which is why I dislike talk of uplisting. I think we're putting the cart before the horse. I think we will have income 1st qtr 2015. I also see a lull of any other significant announcements at that time. I'm hoping that the income from Lympro can cover most of the bills until another product comes online or gets close. Or we are able to capture some other source of funding outside of decreasing shareholder value. If we don't uplist first of 2015, I'm still going to be ok with it.